Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study

被引：49
|
作者：
Brunner, Andrew M.
Esteve, Jordi
Porkka, Kimmo
Knapper, Steve
Vey, Norbert
Scholl, Sebastian
Garcia-Manero, Guillermo
Wermke, Martin
Janssen, Jeroen
Traer, Elie
Loo, Sun
Narayan, Rupa
Tovar, Natalia
Kontro, Mika
Ottmann, Oliver
Naidu, Purushotham
Kurtulus, Sema
Makofske, Jessica
Liao, Serena
Mohammed, Anisa
Sabatos-Peyton, Catherine A.
Rinne, Mikael L.
Borate, Uma
Wei, Andrew H.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-136855
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating drugs (HMAs) in patients with very high or high risk myelodysplastic syndrome (vHR/HR-MDS) and acute myeloid leukemia (AML): final analysis after a phase Ib study
    Brunner, A.
    Porkka, K.
    Knapper, S.
    Traer, E.
    Scholl, S.
    Garcia-Manero, G.
    Vey, N.
    Wermke, M.
    Janssen, J.
    Narayan, R.
    Loo, S.
    Tovar, N.
    Kontro, M.
    Naidu, P.
    Pelletier, M.
    Steensma, D.
    Lewandowski, A.
    Zhang, N.
    Mohammed, A.
    Borate, U.
    Wei, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 35 - 36
  • [2] Anti-TIM-3 Antibody MBG453 in Combination with Hypomethylating Agents (HMAs) in Patients with High-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia: A Phase 1 Study
    Brunner, Andrew
    Borate, Uma
    Esteve, Jordi
    Porkka, Kimmo
    Knapper, Steve
    Vey, Norbert
    Scholl, Sebastian
    Wermke, Martin
    Janssen, Jeroen
    Traer, Elie
    Chua, Chong Chyn
    Narayan, Rupa
    Tovar, Natalia
    Kontro, Mika
    Ottman, Oliver
    Xu, Siyan
    Sun, Haiying
    Naidu, Purushotham
    Szpakowski, Sebastian
    Zhang, Na
    Mohammed, Anisa
    Rinne, Mikael
    Wei, Andrew
    Garcia-Manero, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S188 - S189
  • [3] Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HRMDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study
    Brunner, Andrew M.
    Esteve, Jordi
    Porkka, Kimmo
    Knapper, Steve
    Traer, Elie
    Scholl, Sebasttian
    Garcia-Manero, Guillermo
    Vey, Norbert
    Wermke, Martin
    Janssen, Jeroen
    Narayan, Rupa
    Loo, Sun
    Kontro, Mika
    Ottmann, Oliver
    Naidu, Purushotham
    Pelletier, Marc
    Han, May
    Lewandowski, Andrew
    Zhang, Na
    Mohammed, Anisha
    Rinne, Mikael L.
    Borate, Uma
    Wei, Andrew H.
    Tovar, Natalia
    BLOOD, 2021, 138
  • [4] The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML)
    Zeidan, Amer M.
    Esteve, Jordi
    Giagounidis, Aristoteles
    Kim, Hee-Je
    Miyazaki, Yasushi
    Platzbecker, Uwe
    Schuh, Andre C.
    Sekeres, Mikkael A.
    Westermann, Jorg
    Xiao, Zhijian
    Malek, Kamel
    Scott, Jeffrey
    Niolat, Julie
    Peyrard, Severine
    Ma, Fei
    Kiertsman, Flavia
    Stegert, Mario
    Hertle, Sabine
    Fenaux, Pierre
    Santini, Valeria
    BLOOD, 2020, 136
  • [5] The STIMULUS Clinical Trial Program: Evaluating Combination Therapy with MBG453 in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) or Acute Myeloid Leukemia
    Zeidan, Amer
    Esteve, Jordi
    Kim, Hee-Je
    Miyazaki, Yasushi
    Platzbecker, Uwe
    Schuh, Andre
    Westermann, Joerg
    Malek, Kamel
    Scott, Jeffrey
    Niolat, Julie
    Peyrard, Severine
    Kiertsman, Flavia
    Stegert, Mario
    Fenaux, Pierre
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S188 - S188
  • [6] Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
    Borate, Uma
    Esteve, Jordi
    Porkka, Kimmo
    Knapper, Steve
    Vey, Norbert
    Scholl, Sebastian
    Garcia-Manero, Guillermo
    Wermke, Martin
    Janssen, Jeroen
    Traer, Elie
    Chua, Chong Chyn
    Narayan, Rupa
    Tovar, Natalia
    Kontro, Mika
    Ottmann, Oliver
    Sun, Haiying
    Longmire, Tyler
    Szpakowski, Sebastian
    Liao, Serena
    Patel, Anuradha
    Rinne, Mikael L.
    Brunner, Andrew
    Wei, Andrew H.
    BLOOD, 2019, 134
  • [7] Sabatolimab Plus Hypomethylating Agents (HMAs) in Patients with High-/Very High-risk Myelodysplastic Syndrome (HR/vHR-MDS) and Newly Diagnosed Acute Myeloid Leukemia (ND-AML): Subgroup Analysis of a Phase 1 Study
    Garcia-Manero, Guillermo
    Wei, Andrew H.
    Porkka, Kimmo
    Knapper, Steve
    Traer, Elie
    Scholl, Sebastian
    Vey, Norbert
    Wermke, Martin
    Janssen, Jeroen
    Narayan, Rupa
    Loo, Sun
    Tovar, Natalia
    Kontro, Mika
    Ottmann, Oliver
    Naidu, Purushotham
    Orlando, Elena
    Patel, Nidhi
    Makofske, Jessica
    Ma, Fei
    Zhang, Na
    Mohammed, Anisa
    Rinne, Mikael L.
    Borate, Uma
    Brunner, Andrew M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S350 - S350
  • [8] Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program
    Zeidan, Amer M.
    Al-Kali, Aref
    Borate, Uma
    Cluzeau, Thomas
    DeZern, Amy E.
    Esteve, Jordi
    Giagounidis, Aristoteles
    Kobata, Krissy
    Lyons, Roger
    Platzbecker, Uwe
    Sallman, David A.
    Santini, Valeria
    Sanz, Guillermo
    Sekeres, Mikkael A.
    Wei, Andrew H.
    Xiao, Zhijian
    Van Hoef, Marlies
    Nourry-Boulot, Claire
    Sadek, Islam
    Bengoudifa, Bourras-Rezki
    Sachs, Carolin
    Sabo, John
    Garcia-Manero, Guillermo
    BLOOD, 2021, 138
  • [9] Sabatolimab (MBG453) Combination Treatment Regimens for Patients With Higher-Risk Myelodysplastic Syndromes (HR-MDS): The Myelodysplastic Syndromes Studies in the STIMULUS Immuno-Myeloid Clinical Trial Program
    Zeidan, Amer M.
    Al-Kali, Aref
    Borate, Uma
    Cluzeau, Thomas
    DeZern, Amy E.
    Esteve, Jordi
    Giagounidis, Aristoteles
    Kobata, Krissy
    Lyons, Roger
    Platzbecker, Uwe
    Sallman, David A.
    Santini, Valeria
    Sanz, Guillermo F.
    Sekeres, Mikkael A.
    Wei, Andrew H.
    Xiao, Zhijian
    Van Hoef, Marlies
    Nourry-Boulot, Claire
    Sadek, Islam
    Ma, Fei
    Iordan, Angelica
    Sabo, John
    Garcia-Manero, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S317 - S317
  • [10] Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose
    Wei, Andrew H.
    Esteve, Jordi
    Porkka, Kimmo
    Knapper, Steve
    Vey, Norbert
    Scholl, Sebastian
    Garcia-Manero, Guillermo
    Wermke, Martin
    Janssen, Jeroen
    Traer, Elie
    Loo, Sun
    Narayan, Rupa
    Tovar, Natalia
    Kontro, Mika
    Ottmann, Oliver
    Xu, Siyan
    Liao, Serena
    Stein, Andrew
    Khanshan, Fariba
    Naidu, Purushotham
    Zhang, Na
    Mohammed, Anisa
    Rinne, Mikael L.
    Sun, Haiying
    Brunner, Andrew M.
    Borate, Uma
    BLOOD, 2020, 136
12345